These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29157263)

  • 1. LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.
    Niego B; Broughton BRS; Ho H; Sobey CG; Medcalf RL
    Fluids Barriers CNS; 2017 Nov; 14(1):33. PubMed ID: 29157263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO
    Chen H; Guan B; Chen X; Chen X; Li C; Qiu J; Yang D; Liu KJ; Qi S; Shen J
    Transl Stroke Res; 2018 Oct; 9(5):515-529. PubMed ID: 29275501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematoma expansion in experimental intracerebral hemorrhage is not altered by peracute treatment with recombinant tissue plasminogen activator.
    Pfeilschifter W; Kashefiolasl S; Lauer A; Steinmetz H; Foerch C
    Neuroscience; 2013 Oct; 250():181-8. PubMed ID: 23856067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
    El Amki M; Lerouet D; Coqueran B; Curis E; Orset C; Vivien D; Plotkine M; Marchand-Leroux C; Margaill I
    Exp Neurol; 2012 Dec; 238(2):138-44. PubMed ID: 22921458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
    Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β1 prevents blood-brain barrier damage and hemorrhagic transformation after thrombolysis in rats.
    Cai Y; Liu X; Chen W; Wang Z; Xu G; Zeng Y; Ma Y
    Exp Neurol; 2015 Apr; 266():120-6. PubMed ID: 25708985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
    Cocho D; Borrell M; Martí-Fàbregas J; Montaner J; Castellanos M; Bravo Y; Molina-Porcel L; Belvís R; Díaz-Manera JA; Martínez-Domeño A; Martínez-Lage M; Millán M; Fontcuberta J; Martí-Vilalta JL
    Stroke; 2006 Apr; 37(4):996-9. PubMed ID: 16497981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occlusion under warfarin anticoagulation in mice.
    Ito A; Niizuma K; Shimizu H; Fujimura M; Hasumi K; Tominaga T
    Brain Res; 2014 Aug; 1578():38-48. PubMed ID: 25016287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
    Liu H; Wang Y; Xiao Y; Hua Z; Cheng J; Jia J
    Transl Stroke Res; 2016 Jun; 7(3):209-19. PubMed ID: 27018013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxynitrite Decomposition Catalyst Reduces Delayed Thrombolysis-induced Hemorrhagic Transformation in Ischemia-reperfused Rat Brains.
    Chen HS; Chen XM; Feng JH; Liu KJ; Qi SH; Shen JG
    CNS Neurosci Ther; 2015 Jul; 21(7):585-90. PubMed ID: 25996167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.
    Su EJ; Cao C; Fredriksson L; Nilsson I; Stefanitsch C; Stevenson TK; Zhao J; Ragsdale M; Sun YY; Yepes M; Kuan CY; Eriksson U; Strickland DK; Lawrence DA; Zhang L
    Acta Neuropathol; 2017 Oct; 134(4):585-604. PubMed ID: 28725968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cav-1 Protein Levels in Serum and Infarcted Brain Correlate with Hemorrhagic Volume in a Mouse Model of Thromboembolic Stroke, Independently of rt-PA Administration.
    Gubern-Mérida C; Comajoan P; Huguet G; García-Yebenes I; Lizasoain I; Moro MA; Puig-Parnau I; Sánchez JM; Serena J; Kádár E; Castellanos M
    Mol Neurobiol; 2022 Feb; 59(2):1320-1332. PubMed ID: 34984586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
    Li Y; Zhu ZY; Lu BW; Huang TT; Zhang YM; Zhou NY; Xuan W; Chen ZA; Wen DX; Yu WF; Li PY
    CNS Neurosci Ther; 2019 Dec; 25(12):1343-1352. PubMed ID: 31756041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin Reduces Neuroinflammation in the Hemorrhagic Transformation After rt-PA Treatment in a Mouse Model of Experimental Stroke.
    Lu D; Liu Y; Mai H; Zang J; Shen L; Zhang Y; Xu A
    Front Cell Neurosci; 2018; 12():225. PubMed ID: 30116175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
    Lu HT; Zhao JG; Li MH; Li YD
    Brain Res; 2012 Feb; 1438():75-84. PubMed ID: 22227456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.
    Murakami K; Suzuki M; Suzuki N; Hamajo K; Tsukamoto T; Shimojo M
    Brain Res; 2013 Aug; 1526():84-93. PubMed ID: 23791950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
    Qin Z; Chen L; Liu M; Tan H; Zheng L
    Neurol Sci; 2020 Jan; 41(1):139-147. PubMed ID: 31478148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.
    Pfeilschifter W; Bohmann F; Baumgarten P; Mittelbronn M; Pfeilschifter J; Lindhoff-Last E; Steinmetz H; Foerch C
    Ann Neurol; 2012 May; 71(5):624-33. PubMed ID: 22447744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.
    Martí-Fàbregas J; Bravo Y; Cocho D; Martí-Vilalta JL; Díaz-Manera J; San Román L; Puig M; Blanco M; Castellanos M; Millán M; Roquer J; Obach V; Maestre J
    Cerebrovasc Dis; 2007; 23(2-3):85-90. PubMed ID: 17114877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.
    Roveri L; La Gioia S; Ghidinelli C; Anzalone N; De Filippis C; Comi G
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):703-8. PubMed ID: 22133742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.